Top 11 uveitis papers for residents

Edited by: Justine R. Smith, MD, PhD
American Uveitis Society AAO Education Liaison

The following 11 uveitis papers published in 2015 were selected by members of the American Uveitis Society (AUS) for their outstanding teaching value for residents:

1. Bhatt N, Dalal M, Tucker W, Obiyor D, Nussenblatt R, Sen HN. Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial. Am J Ophthalmol. 2015; 159: 601-6.
2. Kothari S, Foster CS, Pistilli M, Liesegang TL, Daniel E, Sen HN, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Lawrence SD, Kempen JH; Systemic Immunosuppressive Therapy for Eye Diseases Research Group. The risk of intraocular pressure elevation in pediatric noninfectious uveitis. Ophthalmology. 2015; 122: 1987-2001.
3. Messenger W, Hildebrandt L, Mackensen F, Suhler E, Becker M, Rosenbaum JT. Characterisation of uveitis in association with multiple sclerosis. Br J Ophthalmol. 2015; 99: 205-9.
4. Moradi A, Salek S, Daniel E, Gangaputra S, Ostheimer TA, Burkholder BM, Leung TG, Butler NJ, Dunn JP, Thorne JE. Clinical features and incidence rates of ocular complications in patients with ocular syphilis. Am J Ophthalmol. 2015; 159: 334-43.e1.
5. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Quality of life and risks associated with systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, or panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment Trial and follow-up study. Ophthalmology. 2015; 122: 1976-86.
6. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and follow-up study. Ophthalmology. 2015; 122: 1967-75.
7. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Van Natta ML, Altaweel MM, Dunn JP, Jabs DA, Lightman SL, Thorne JE, Holbrook JT. Factors predicting visual acuity outcome in intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment (MUST) Trial. Am J Ophthalmol. 2015; 160: 1133-1141.e9.
8. Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group. Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results. Ophthalmology. 2015; 122: 2351-9.
9. Varkey JB, Shantha JG, Crozier I, Kraft CS, Lyon GM, Mehta AK, Kumar G, Smith JR, Kainulainen MH, Whitmer S, Ströher U, Uyeki TM, Ribner BS, Yeh S. Persistence of ebola virus in ocular fluid during convalescence. N Engl J Med. 2015; 372: 2423-7.
10. Yates WB, Vajdic CM, Na R, McCluskey PJ, Wakefield D. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study. Ophthalmology. 2015; 122: 265-73.  
    Editorial: Khachatryan N, Kempen JH. Immunosuppressive therapy and cancer risk in ocular inflammation patients: fresh evidence and more questions. Ophthalmology. 2015; 122: 219-21.
11. Yuen BG, Tham VM, Browne EN, Weinrib R, Borkar DS, Parker JV, Uchida A, Vinoya AC, Acharya NR. Association between smoking and uveitis: results from the pacific ocular inflammation study. Ophthalmology. 2015 Jun;122(6):1257-61.

An American Uveitis Society Publication

Contributors:

Nisha Acharya, MD, MS; Tayyeba Ali, MD, Maria Bernal, MD, Pooja Bhat, MD; Nicholas J. Butler, MD; David Callanan, MD; Janet L. Davis, MD; James P. Dunn, MD; Albert Edwards, MD, Anthony S. Ekong, MD; Lisa Faia, MD, Naomi Falk, OD, MD, Paul Gaudio, MD, William Godfrey, MD, Debra A. Goldstein, MD; Sumit Gupta, MD, David Hinkle, MD, Gary N. Holland, MD, Guy Jirawuthiworavong, MD, MA; Kashyap Kansupada, MD, FACS; Henry J. Kaplan, MD; Sanjay R. Kedhar, MD; Shree K. Kurup, MD; Daryl Kurz, MD, Kelly L. Larkin, MD; Paul Latkany, MD; Shelly T. Lee, MD; Ralph Levinson, MD; Grace A. Levy-Clarke MD; Richard Lewis, MD, MS, Helen K. Li, MD; Careen Y. Lowder, MD; Virginia Miraldi Utz, MD; Ramana S. Moorthy, MD; Deanne Nakamoto, MD, Armando Oliver, MD, E. Mitchel Opremcak, MD; Alan Palestine, MD, Sirichai Pasadhika, MD, Parvathy Pillai, MD, Narsing A. Rao, MD; Prabakar Rao, MD, Russell W. Read, MD, PhD; Damien Rodger MD, PhD, Shlomit Schaal, MD, PhD; Anita P. Schadlu, MD; Mark D. Sherman; MD, Jerry A. Shields; MD, Lucia Sobrin, MD, MPH, Justine R. Smith, FRANZCO, PhD; Robert Swan, MD, Byron Tabbut, MD, Howard H. Tessler, MD; Jennifer E. Thorne, MD, PhD; Jonathan Walker, MD; Christopher Walton, MD.

Acknowledgement:

The American Uveitis Society thanks Ms. Deb Sullivan for her administrative assistance in preparing this publication.